A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This Phase 3 study will evaluate the safety and efficacy of JADE101 compared with placebo in adults with immunoglobulin A nephropathy (IgAN). The results will contribute to the overall clinical characterization of JADE101 in this patient population.
Epistemonikos ID: 6920494dd7821912d8d5ac02af6d60af3861a653
First added on: Oct 30, 2026